Product Overview
[Drug Name]
Generic Name: Candesartan Cilexetil Tablets
Trade Name: Boligo
English Name: Candesartan Cilexetil Tablets
Chinese Pinyin: Kandishatanzhi Pian
[Ingredients]
Candesartan Cilexetil.
[Properties]
This product is white or off-white tablets.
[Indications]
For the treatment of essential hypertension. This product can be used alone or in combination with other antihypertensive drugs.
[Dosage and Administration]
Oral administration. Generally, adults take 4-8 mg once a day. The dose can be increased to 12 mg if necessary.
[Adverse Reactions]
1. Serious adverse reactions (incidence unknown): (1) Angioedema: Angioedema with symptoms of edema of the face, lips, tongue, pharynx, and larynx sometimes occurs. Careful observation should be conducted. If abnormalities are observed, the drug should be discontinued and appropriate treatment should be given. (2) Syncope and loss of consciousness: Excessive blood pressure reduction may cause syncope and temporary loss of consciousness. In this case, the drug should be discontinued and appropriate treatment should be implemented. In particular, patients undergoing hemodialysis, patients undergoing strict salt restriction therapy, and patients who have recently started taking diuretic antihypertensive drugs may experience a rapid drop in blood pressure. Therefore, these patients should start treatment with this drug at a lower dose. If it is necessary to increase the dose, the patient should be closely observed and the dosage should be increased slowly. (3) Acute renal failure: Acute renal failure may occur. The patient's condition should be closely observed. If abnormalities are found, the drug should be discontinued and appropriate treatment should be implemented. (4) Patients with hyperkalemia: Given the possibility of hyperkalemia, the patient's condition should be closely observed. If abnormalities are found, the drug should be discontinued and appropriate treatment should be implemented. (5) Deterioration of liver function or jaundice: Given the possibility of liver dysfunction or jaundice with elevated AST (GOT), ACT (GPTO, γ-GTP), etc., the patient's condition should be closely observed. If abnormalities are found, the drug should be discontinued and appropriate treatment should be implemented. (6) Agranulocytosis: Agranulocytosis may occur. The patient's condition should be closely observed. If abnormalities are found, the drug should be discontinued and appropriate treatment should be implemented. (7) Rhabdomyolysis: Symptoms such as myalgia, weakness, increased CK, and myosin in the blood and urine may occur. If the above symptoms occur, the drug should be stopped and appropriate treatment should be given. (8) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, dyspnea, and abnormal chest X-ray examination may occur. If the above symptoms occur, the drug should be stopped and appropriate treatment should be given, such as treatment with corticosteroids.
[Contraindications]
1. Patients with a history of allergy to the ingredients of this preparation.
2. Pregnant or potentially pregnant women.
3. Patients with severe liver or kidney dysfunction or cholestasis.
[Precautions]
1. Use the drug with caution (the drug should be used with caution in the following patients) (1) Patients with bilateral or unilateral renal arteries (see 2 Important Basic Precautions). (2) Patients with hyperkalemia (see 2 Important Basic Precautions). (3) Patients with liver dysfunction (liver function may worsen. In addition, it is speculated that the clearance rate of the active metabolite candesartan is reduced, so it should be started at a low dose and used with caution). (4) Patients with severe renal dysfunction (due to excessive blood pressure reduction, renal function may worsen, so it should be taken once a day, starting with 2 mg, and used with caution). (5) Patients with a history of drug allergies. (6) Elderly patients). (7) Kidney transplantation: There is no experience with the use of this product in patients who have recently undergone kidney transplantation. (8) Stenosis of the great arteries and left atrioventricular valve (obstructive cardiomyopathy): Patients using other vasodilators, especially those with hemodynamically relevant stenosis of the great arteries or left atrioventricular valve or obstructive cardiomyopathy, should use this product with caution. (9) Mild to moderate hyperadrenocorticism: Patients with mild to moderate hyperadrenocorticism usually do not respond to antihypertensive drugs that inhibit the renin-angiotensin and aldosterone systems, so it is not recommended to take this product. 2. Important basic precautions (1) Patients with bilateral or unilateral renal artery stenosis who take drugs that regulate the renin-angiotensin-aldosterone system may face increased risks to renal function due to decreased renal blood flow and filtration pressure. Therefore, the use of this drug should be avoided unless it is considered necessary for treatment. (2) Because it may aggravate hyperkalemia, patients with hyperkalemia should avoid taking this drug unless it is considered necessary for treatment. In addition, patients with uncontrolled diabetes and renal dysfunction should pay close attention to their blood potassium levels because these patients are prone to developing hyperkalemia. (3) Since the use of this preparation may sometimes cause a sharp drop in blood pressure, it should be started with a small dose, and when increasing the dose, the patient's condition should be carefully observed and the dosage should be increased slowly. A. Patients undergoing hemodialysis. B. Patients undergoing strict salt restriction therapy. C. Patients taking diuretic antihypertensive drugs (especially those who have recently started taking diuretic antihypertensive drugs). (4) Due to the antihypertensive effect, dizziness and staggering may sometimes occur. Therefore, caution should be exercised when performing operations such as working at heights and driving a vehicle. (5) It is best to stop taking this drug 24 hours before surgery. (6) When the drug is delivered: the drug packaged in the PTP should be taken after it is taken from the PTP sheet (there have been reports of accidental ingestion of the hard sharp corners of the PTP sheet piercing the esophageal mucosa, which has led to perforation and complications such as mediastinitis).
[Special population medication]
Children's precautions: The safety of the drug for children has not been determined (no use test)Precautions during pregnancy and lactation: This product is contraindicated for pregnant or potentially pregnant womenPrecautions for the elderly: It is generally believed that blood pressure should not be excessively lowered in the elderly (it may cause cerebral infarction, etc.). It should be taken with caution while the patient is under observation. The starting dose for elderly people with normal liver and kidney function is 4 mg. The recommended starting dose for patients with renal or hepatic insufficiency is 2 mg. The dose needs to be increased or decreased according to the condition.
[Drug Interactions]
Be careful when using the drug together (caution should be taken when using the drug together) This product has no significant interaction with drugs such as glyburide, nimodipine, digoxin, warfarin, and hydrochlorothiazide. There is also no significant interaction when taking oral contraceptives in healthy subjects.
[Pharmacological Actions]
Candesartan cilexetil is rapidly hydrolyzed in vivo into its active metabolite, candesartan. Candesartan is a selective angiotensin II receptor (AT1) antagonist. It binds to AT1 receptors on vascular smooth muscle, antagonizing the vasoconstrictive effects of angiotensin II and thereby reducing peripheral vascular resistance. It is also believed that candesartan exerts a certain antihypertensive effect by inhibiting adrenal aldosterone secretion. Candesartan does not inhibit kininase II and does not affect bradykinin degradation. Experiments in patients with hypertension have shown that repeated use of this drug can increase plasma renin activity, angiotensin I, and angiotensin II concentrations. Continuous daily administration of 2-8 mg of this drug can reduce systolic and diastolic blood pressure, left ventricular myocardial mass, and peripheral vascular resistance, while having no significant effect on cardiac output, ejection fraction, renal vascular resistance, renal blood flow, or glomerular filtration rate. It has no effect on cerebral blood flow in patients with primary hypertension and cerebrovascular disease.
Storage: Store in a dry, sealed container.
Strength: 8mg
Packaging: 8mg x 7 tablets
Expiry Period: Tentatively 24 months
Approval Number: National Medicine Standard H20050323
Manufacturer: Zhejiang Yongning Pharmaceutical Co., Ltd.
